The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?

CNS Drugs
Paul HodgkinsFloyd R Sallee

Abstract

Attention-deficit hyperactivity disorder (ADHD) treatment options include pharmacological and nonpharmacological approaches. In North America, psychostimulants (amphetamine and methylphenidate) are considered first-line pharmacological treatments for patients (children, adolescents and adults) with ADHD. However, in the UK, National Institute for Health and Clinical Excellence (NICE) guidelines have placed short-acting d-amphetamine as a third-line treatment option due to a lack of contemporary, published clinical trials on its efficacy and the concerns from clinical and patient experts regarding the potential for increased abuse and/or misuse compared with methylphenidate. These guidelines do not account for some of the more recent amphetamine products that have been developed to alleviate some of these concerns, but that are not currently approved in the UK or other European countries. The purpose of this review is to describe the pharmacology and clinical efficacy of various amphetamine compositions, as well as to explore the apparent differences in these compositions and their associated risks and benefits. A PubMed literature search was conducted to investigate amphetamine pharmacology, clinical efficacy and safety and ADH...Continue Reading

References

Dec 1, 1991·British Journal of Addiction·M Farré, J Camí
Jul 1, 1990·Journal of the American Academy of Child and Adolescent Psychiatry·R A BarkleyL Smallish
Mar 1, 1986·Clinical Pharmacokinetics·U Busto, E M Sellers
Mar 1, 1995·Clinical Pharmacology and Therapeutics·G K MumfordR R Griffiths
May 1, 1996·Archives of General Psychiatry·J BiedermanJ Perrin
Nov 1, 1996·Comprehensive Psychiatry·K Murphy, R A Barkley
May 20, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·J M SwansonD P Cantwell
Sep 14, 1999·The Australian and New Zealand Journal of Psychiatry·R PatersonZ Krupenia
Dec 28, 1999·Pediatrics·S Auster
May 10, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·S R PliszkaS K Wynne
Feb 24, 2001·Journal of Child and Adolescent Psychopharmacology·F B Taylor, J Russo
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·J M SwansonM Wu
Nov 9, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·R S JamesF X Castellanos
Jan 11, 2002·Clinical Child and Family Psychology Review·C Johnston, E J Mash
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Frank P BymasterKenneth W Perry
Aug 19, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·James T McCrackenSimon Tulloch
Oct 16, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Laurence L GreenhillSimon Tulloch
Nov 5, 2003·The American Journal of Psychiatry·Nora D Volkow, James M Swanson
Nov 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Andrine R SwensenAmi Claxton
Mar 12, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Andrew R. Adesman
Aug 24, 2004·European Child & Adolescent Psychiatry·Eric TaylorAlessandro Zuddas
Jan 27, 2005·Journal of Attention Disorders·L EakinK Looper
May 24, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·James J McGoughSimon J Tulloch
Jul 12, 2005·Pharmacotherapy·Robert J SanchezJames P Wilson
Jul 19, 2005·Lancet·Joseph Biederman, Stephen V Faraone
May 9, 2006·European Child & Adolescent Psychiatry·Tobias BanaschewskiEric Taylor
May 25, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Steven R PliszkaUNKNOWN TEXAS CONSENSUS CONFERENCE PANEL ON PHARMACOTHERAPY OF CHILDHOOD ATTENTION DEFICIT HYPERACTIVITY DISORDER

❮ Previous
Next ❯

Citations

May 3, 2014·CNS Drugs·David R CoghillRichard Civil
Jun 26, 2014·BMC Veterinary Research·Zengyang Pei, Xu Zhang
Jun 21, 2014·Expert Review of Neurotherapeutics·Carlos Roncero, F Javier Álvarez
Mar 25, 2014·Pharmacology & Therapeutics·Peter H HutsonAshwin A Patkar
Apr 7, 2016·CNS Drugs·James E Frampton
Aug 28, 2016·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Geir OgrimJan Ferenc Brunner
Dec 17, 2015·Journal of Correctional Health Care : the Official Journal of the National Commission on Correctional Health Care·Duncan A ScottGunter W Lorberg
Apr 6, 2018·Journal of Clinical Psychopharmacology·Maikel HerbrinkWim van den Brink
Apr 27, 2018·The Journal of Clinical Pediatric Dentistry·Puneet WadhwaJanice A Townsend
Nov 4, 2017·The International Journal of Neuropsychopharmacology·Thomas LiebeMartin Walter
Oct 5, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ann C ChildressF Randy Sallee
May 1, 2020·Journal of Psychosocial Nursing and Mental Health Services·Barbara J Limandri
May 10, 2017·Drug and Alcohol Review·Blanca Iciar IndaveGregorio Barrio
Dec 4, 2020·Genes·Heejin Kam, Hotcherl Jeong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.